Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 11, 2014, Pages 1550-1559

  Mastalerz, L ^a   Celejewska Wojcik N ^a   Wojcik K ^a   Gielicz, A ^a   Januszek, R ^a   Cholewa, A ^a   Strek P ^a   Sanak, M ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

aspirin exacerbated respiratory disease; eicosanoids; induced sputum; leukotrienes; prostaglandin E2

Indexed keywords

11 OXOTHROMBOXANE B2; 5,12,15 HYDROXYEICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; LEUKOTRIENE B4; LEUKOTRIENE D4; LEUKOTRIENE E4; LIPOXYGENASE; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; UNCLASSIFIED DRUG; IMMUNOGLOBULIN E; LEUKOTRIENE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN;

ADULT; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; BRONCHOCONSTRICTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION TEST; LEUKOCYTE DIFFERENTIAL COUNT; MASS FRAGMENTOGRAPHY; METABOLITE; PHENOTYPE; SPUTUM; SPUTUM CYTODIAGNOSIS; SUPERNATANT; VALIDATION PROCESS; AGED; ASTHMA, ASPIRIN-INDUCED; BLOOD; CYTOLOGY; DISEASE COURSE; IMMUNOLOGY; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA, ASPIRIN-INDUCED; BRONCHIAL PROVOCATION TESTS; DISEASE PROGRESSION; DRUG HYPERSENSITIVITY; EICOSANOIDS; FORCED EXPIRATORY VOLUME; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; IMMUNOGLOBULIN E; LEUKOTRIENES; MIDDLE AGED; PROSTAGLANDINS; RESPIRATORY FUNCTION TESTS; SPUTUM;

EID: 84907932955     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12512     Document Type: Article

References (45)

1. Dente FL, Carnevali S, Bartoli ML, Cianchetti S, Bacci E, Di Franco A, et al. Profiles of proinflammatory cytokines in sputum from different groups of severe asthmatic patients. Ann Allergy Asthma Immunol 2006; 97: 312-320.
2. Boyce JA,. Eicosanoids in asthma, allergic inflammation, and host defence. Curr Mol Med 2008; 8: 335-349.
3. Szczeklik A, Stevenson DD,. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111: 913-921.
4. Berges-Gimeno MP, Simon RA, Stevenson DD,. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89: 474-478.
5. Szczeklik A, Sanak M,. The broken balance in aspirin hypersensitivity. Eur J Pharmacol 2006; 533: 145-155.
6. Szczeklik A, Mastalerz L, Nizankowska E, Ćmiel A,. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996; 153: 567-571.
7. 4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996; 153: 572-575.
8. 2. Lancet 1994; 344: 436-438.
9. Higashi N, Taniguchi M, Mita H, Yamagichi H, Ono E, Akiyama K,. Aspirin-intolerant asthma (AERD) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites. Allergol Int 2012; 61: 393-403.
10. Schafer D, Schmid M, Gode UC, Baenkler HW,. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur Respir J 1999; 13: 638-646.
11. Kowalski ML, Pawliczak R, Woźniak J, Siuda K, Poniatowska M, Iwaszkiewicz J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000; 161: 391-398.
12. Kowalski ML, Ptasińska A, Bienkiewicz B, Pawliczak R, DuBuske I,. Differential effects of aspirin and misoprostol on 15-hydroxyeicosatetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients. J Allergy Clin Immunol 2003; 112: 505-512.
13. 2 production by bronchial fibroblasts of asthmatic patients with special reference to aspirin-induced asthma. J Allergy Clin Immunol 2003; 111: 1041-1048.
14. Picado C, Femandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A, et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1999; 160: 291-296.
15. Perez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C,. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol 2005; 115: 1189-1196.
16. Ying S, Meng Q, Scadding G, Parikh A, Corrigan CJ, Lee TH,. Aspirin sensitive rhinosinusitis is associated with reduce E-prostanoid 2 (EP2) receptor expression on nasal mucosal inflammatory cells. J Allergy Clin Immunol 2006; 117: 312-318.
17. 2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum Mol Genet 2004; 13: 3203-3217.
18. 2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax 2008; 63: 27-34.
19. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL,. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988; 137: 847-854.
20. Sładek K, Dworski R, Soja J, Sheller JR, Nizankowska E, Oates JA, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149: 940-946.
21. Campo P, Ayuso P, Salas M, Plaza MC, Cornejo-Garcia JA, Doña I, et al. Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs. Allergy 2013; 68: 1001-1007.
22. Fanning LB, Boyce JA,. Lipid mediators and allergic diseases. Ann Allergy Asthma Immunol 2013; 111: 155-162.
23. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143: 1025-1029.
24. 4, and histamine in asthmatics. Am Rev Respir Dis 1992; 146: 96-103.
25. Higashi N, Mita H, Ono E, Fukutomi Y, Yamaguchi H, Kajiwara K, et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010; 125: 1084-1091.
26. Gaber F, Daham K, Higashi A, Higashi N, Gulich A, Delin I, et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin intolerant asthma. Thorax 2008; 63: 1076-1082.
27. Mastalerz L, Sanak M, Gawlewicz A, Gielicz A, Faber J, Szczeklik A,. Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria. J Allergy Clin Immunol 2006; 118: 957-958.
28. 2 and aspirin-induced asthma. Lancet 1995; 345: 1056.
29. 2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003; 111: 743-749.
30. Sanak M, Gielicz A, Bochenek G, Kaszuba M, Nizankowska-Mogilnicka E, Szczeklik A,. Targeted eicosanoids lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. J Allergy Clin Immunol 2011; 127: 1141-1147.
31. Sanak M, Kiełbasa B, Bochenek G, Szczeklik A,. Exhaled eicosanoids following oral aspirin challenge in asthmatic patients. Clin Exp Allergy 2004; 34: 1899-1904.
32. Mastalerz L, Kumik J, Kasperkiewicz H, Kaszuba M, Stręk P, Sanak M,. Altered metabolism of prostaglandin E2 in asthma patients with aspirin hypersensitivity. Pol Arch Med Wewn 2013; 123: 423-424.
33. Szczeklik A, Sładek K, Dworski R, Nizankowska E, Soja J, Sheller J, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996; 154: 1608-1614.
34. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, ͆wierczyńska M, Picado C, Scadding G, et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62: 1111-1118.
35. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE,. Standardised methodology of sputum induction and processing. Eur Respir J 2002; 20: 1-55.
36. Higashi A, Kumlin M, Higashi N, Daham K, Gaber F, Lindeberg A, et al. Challenge of isolated sputum cells supports in vivo origin of intolerance reaction to aspirin/non-steroidal anti-inflammatory drugs in asthma. Int Arch Allergy Immunol 2012; 158: 299-306.
37. Sanak M, Gielicz A, Nagraba K, Kaszuba M, Kumik J, Szczeklik A,. Targeted eicosanoids lipidomics of exhaled breath condensate in healthy subjects. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1796-1800.
38. Picado C, Ramis I, Rosello J, Prat J, Bulbena O, Plaza V, et al. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin sensitive asthmatic patients. Am Rev Respir Dis 1992; 145: 65-69.
39. Chou W-L, Chuang L-M, Chou C-C, Wang AH-J, Lawson JA, FitzGerald G, et al. Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome-proliferator-activated receptor γ receptor. J Biol Chem 2007; 282: 18162-18172.
40. Daham K, Song WL, Lawson JA, Kupczyk M, Gülich A, Dahlén SE, et al. Effects of celecoxib on major prostaglandins in asthma. Clin Exp Allergy 2011; 41: 36-45.
41. Fajt ML, Gelhaus SL, Freeman B, Uvalle CE, Trudeau JB, Holguin F, et al. Prostaglandin D pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol 2013; 131: 1504-1512.
42. Folco G, Murphy RC,. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue response. Pharmacol Rev 2006; 58: 375-388.
43. Liu T, Laidlaw TM, Katz HR, Boyce JA,. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci USA 2013; 110: 16987-16992.
44. Sánchez-Viduarre S, Cruz MJ, Gõmez-Ollés S, Morell F, Muñoz X,. Sputum inflammatory profile before and after specific inhalation challenge in individuals with suspected occupational asthma. PLoS ONE 2013; 8: e78304.
45. Obase Y, Shimoda T, Tomari SY, Mitsuta K, Kawano T, Matsuse H, et al. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. Chest 2002; 121: 143-150.